AHL Investment Management Inc. Acquires 6,345 Shares of Pfizer Inc. (NYSE:PFE)

AHL Investment Management Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 7.4% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 91,782 shares of the biopharmaceutical company’s stock after purchasing an additional 6,345 shares during the period. Pfizer accounts for approximately 1.6% of AHL Investment Management Inc.’s portfolio, making the stock its 24th largest position. AHL Investment Management Inc.’s holdings in Pfizer were worth $2,326,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PFE. D Orazio & Associates Inc. grew its stake in Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 391 shares in the last quarter. Lipe & Dalton boosted its holdings in shares of Pfizer by 17.7% in the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 400 shares during the period. Beam Wealth Advisors Inc. grew its position in shares of Pfizer by 1.5% in the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock valued at $728,000 after purchasing an additional 401 shares in the last quarter. Providence Capital Advisors LLC raised its stake in shares of Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after purchasing an additional 409 shares during the period. Finally, Donaldson Capital Management LLC lifted its holdings in Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock worth $947,000 after purchasing an additional 410 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.0%

NYSE PFE opened at $23.36 on Monday. The stock’s 50-day simple moving average is $22.95 and its two-hundred day simple moving average is $25.00. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $132.81 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.82 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.36%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PFE shares. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group boosted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.